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DUC4
HIGH USERS OF 2-AGONISTS: ARE MEDICAID 
RECIPIENTS BEING TREATED ACCORDING TO 
NATIONAL ASTHMA GUIDELINES?
Reddy P1, Kelly E1, Kophazi M2, Geary E3, Markelon J1, 
Welter K1
1Pharmacy School, University of Connecticut, Storrs, CT, USA; 
2Health Information Design Inc., Auburn, AL, USA; 
3Connecticut Medicaid Department, Hartford, CT, USA
Studies have shown an association between increased use
of 2-agonists and risk of death. Little information is
available on the appropriateness of asthma management
in Medicaid populations although data suggest that Med-
icaid recipients experience higher healthcare utilization
than non-Medicaid recipients. OBJECTIVE: To deter-
mine whether Medicaid’s high dose 2-agonists (HDB)
users (1 inhaler/month) are being managed according
to National Institute of Health (NIH) asthma guidelines.
METHODS: All Connecticut Medicaid pharmacy claims
from April to December 1998 were examined. Subjects
were included if they had an asthma diagnosis and were
5 years old. Subjects were excluded if they had chronic
obstructive airway disease or a claim for ipratropium.
The percent of HDB users receiving (1) no long-term con-
troller (LTC  inhaled corticosteroid, theophylline, leu-
kotriene modifier, mast cell stabilizer); (2) low doses of a
LTC; (3) oral or nebulized 2-agonists; (4) spacers or
peak flow meters was determined. RESULTS: A total of
1596 profiles were included (42  16 years, mean 
SD;79% female); 178 were excluded. Fourteen percent
were HDB users; of these 24% did not have a claim for a
LTC and 29% received low doses of a LTC. Oral or neb-
ulized 2-agonists claims were submitted by 34% of HDB
users. Seven percent and 0% of HDB users submitted
claims for spacers and peak flow meters, respectively.
CONCLUSION: A high proportion of Medicaid asthma
patients who are HDB users are not being managed ac-
cording to recent NIH guidelines. Intervention programs
designed to improve adherence to the guidelines will be
developed.
Methodologic Issues/Advances MI
MI1
IDENTIFYING FACTORS ASSOCIATED WITH 
HIGH AND LOW COST ASTHMATICS: 
OPPORTUNITIES FOR DISEASE MANAGEMENT 
USING AUTOMATIC 
INTERACTION DETECTION
Boscarino JA, Zhao Z, Andrews KW, Sokol MC, Yao J, 
McGuigan KA, Gutierrez B, Refowitz, R
Merck-Medco Managed Care, Franklin Lakes, NJ, USA
Because the costs of treating asthmatic patients vary, we
wanted to develop cost-effective health management strat-
egies by identifying factors associated with high and low
cost patients. METHODS: We integrated 24 months of
medical and drug claims data for 89,245 individuals who
had health benefits through two large US companies. In-
dividuals were defined as asthmatics if they had two or
more asthma medical or asthma drug claims over the first
12 months. 1,529 asthmatics (mean age  38; females 
56%) were included in our study, after excluding those
under age 5, over age 64, and COPD cases. We predicted
costs in the second year based on first-year risk factors,
using a recursive partitioning, Chi-squared Automatic In-
teraction Detection (CHAID) model. Predictor variables
included: age, gender, region, member status, and 18 co-
morbidities based on the ICD-9 body-system method.
RESULTS: We found higher average costs associated
with asthmatics that had either circulatory disorders
($6,796, P  0.0001) or cancers ($6,381, P  0.009).
However, asthmatics with circulatory and mental disor-
ders ($20,035, P  0.0001), digestive and nervous sys-
tem disorders ($12,447, P  0.008), and those with cir-
culatory and nervous system disorders ($11,633, P 
0.0001) had the highest average costs. Conversely, the
lowest costs were associated with 6–39 year old, male
($691, P  0.03) and female ($1331, P  0.05) asthmat-
ics without comorbidities. The R2 for the CHAID model
was similar to stepwise regression (both approximately
12% for actual dollars and 30% for log dollars), and
most of the variables selected were the same. CONCLU-
SIONS: Our analysis identified high and low cost asth-
matic patients and may be useful in guiding future inter-
ventions. In order to reduce health care costs, for
example, our study suggests asthmatics with concurrent
circulatory and mental health disorders may warrant in-
tense interventions, while younger male asthmatics with-
out comorbidities may not.
MI2
THE NUMBER NEEDED TO TREAT APPROACH: 
EVALUATING THE CLINICAL RELEVANCE OF 
FEXOFENADINE IN SEASONAL 
ALLERGIC RHINITIS
Crawford B1, Marquis P2, Offord S3
1MAPI Values, Boston, MA, USA; 2MAPI Values, Lyon, France; 
3Aventis Pharmaceuticals, Inc, Bridgewater, NJ, USA
The use of minimal important difference (MID) in quality
of life assessment has grown recently in an effort to make
measured changes more meaningful to the practicing
physician. The use of MID, however, does not take into
account the distribution of response, only the mean. OB-
JECTIVE: To examine the use of number needed to treat
(NNT) in seasonal allergic rhinitis as a valid and more
relevant approach to present data from clinical trials to
physicians. METHODS: 538 subjects completed the Rhi-
noconjunctivitis Quality of Life Questionnaire (RQLQ),
a symptom questionnaire, and a self-reported change
scale. These data were used to determine meaningful
changes in the RQLQ and generate a 3  3 table to cal-
culate the NNT. RESULTS: We examined data from the
STAR study comparing fexofenadine, loratadine and pla-
